Hepatocellular carcinoma (HCC) stands as the most prevalent form of liver cancer and is a leading cause of cancer-related fatalities worldwide. The efficacy of conventional therapeutic approaches like surgical resection, transplantation, and chemotherapy is limited, underscoring the pressing need for innovative treatment strategies. Antibody-based immunotherapy has emerged as a promising approach in the battle against HCC. Substantial progress has been made in the field of antibody-based immunotherapies for HCC, encompassing the development of these treatments and their successful integration into clinical practice. Monoclonal antibodies targeting specific immunological checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have demonstrated notable therapeutic efficacy in a specific subset of HCC patients. Additionally, advancements in cancer vaccines, including those based on peptides, DNA, and dendritic cells, hold considerable potential in eliciting targeted immune responses against HCC.
The objective of this Research Topic issue is to provide thorough information on the recent advancements in antibody-based immunotherapy for hepatocellular carcinoma (HCC), with a particular emphasis on the advancement of a cancer vaccine. We believe that this special issue will provide a comprehensive overview of the latest advancements, stimulate collaboration, and inspire additional research to improve the outcomes for patients with HCC.
We warmly invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews that focus primarily on, but not limited to, the following subtopics:
1. Research conducted on the use of antibody-based immunotherapies for hepatocellular carcinoma (HCC), including both preclinical and clinical investigations.
2. Understanding the mechanisms by which antibody-based therapeutics exert their effects and identifying the factors that contribute to resistance against these therapies.
3. Exploration of novel targets and treatment approaches for antibody-based immunotherapy.
4. Combination of antibodies with other therapy techniques.
5. Progress in cancer vaccines for HCC, encompassing the identification of antigens, development of vaccine designs, and running clinical trials.
6. Biomarkers for patient selection and response prediction in antibody-based immunotherapy.
7. Evaluation of the safety profiles and strategies for managing immune-related adverse events.
8. Prospects and challenges in the area of antibody-based immunotherapy for HCC.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Anwaar Saeed reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords:
Hepatocellular Carcinoma, antibody-based immunotherapy, Monoclonal antibodies, cancer vaccine, checkpoints inhibitors
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
Hepatocellular carcinoma (HCC) stands as the most prevalent form of liver cancer and is a leading cause of cancer-related fatalities worldwide. The efficacy of conventional therapeutic approaches like surgical resection, transplantation, and chemotherapy is limited, underscoring the pressing need for innovative treatment strategies. Antibody-based immunotherapy has emerged as a promising approach in the battle against HCC. Substantial progress has been made in the field of antibody-based immunotherapies for HCC, encompassing the development of these treatments and their successful integration into clinical practice. Monoclonal antibodies targeting specific immunological checkpoints, such as programmed cell death protein 1 (PD-1) and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), have demonstrated notable therapeutic efficacy in a specific subset of HCC patients. Additionally, advancements in cancer vaccines, including those based on peptides, DNA, and dendritic cells, hold considerable potential in eliciting targeted immune responses against HCC.
The objective of this Research Topic issue is to provide thorough information on the recent advancements in antibody-based immunotherapy for hepatocellular carcinoma (HCC), with a particular emphasis on the advancement of a cancer vaccine. We believe that this special issue will provide a comprehensive overview of the latest advancements, stimulate collaboration, and inspire additional research to improve the outcomes for patients with HCC.
We warmly invite the submission of Original Research, Brief Research Reports, Reviews, and Mini-Reviews that focus primarily on, but not limited to, the following subtopics:
1. Research conducted on the use of antibody-based immunotherapies for hepatocellular carcinoma (HCC), including both preclinical and clinical investigations.
2. Understanding the mechanisms by which antibody-based therapeutics exert their effects and identifying the factors that contribute to resistance against these therapies.
3. Exploration of novel targets and treatment approaches for antibody-based immunotherapy.
4. Combination of antibodies with other therapy techniques.
5. Progress in cancer vaccines for HCC, encompassing the identification of antigens, development of vaccine designs, and running clinical trials.
6. Biomarkers for patient selection and response prediction in antibody-based immunotherapy.
7. Evaluation of the safety profiles and strategies for managing immune-related adverse events.
8. Prospects and challenges in the area of antibody-based immunotherapy for HCC.
Manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by robust and relevant validation (clinical cohort or biological validation in vitro or in vivo) are out of scope for this topic.
Topic editor Anwaar Saeed reports a leadership role with Autem therapeutics, Exelixis, KAHR medical and Bristol-Myers Squibb; consulting or advisory board role with AstraZeneca, Bristol-Myers Squibb, Merck, Exelixis, Pfizer, Xilio therapeutics, Taiho, Amgen, Autem therapeutics, KAHR medical, and Daiichi Sankyo; institutional research funding from AstraZeneca, Bristol-Myers Squibb, Merck, Clovis, Exelixis, Actuate therapeutics, Incyte Corporation, Daiichi Sankyo, Five prime therapeutics, Amgen, Innovent biologics, Dragonfly therapeutics, Oxford Biotherapeutics, Arcus therapeutics, and KAHR medical; and participation as a data safety monitoring board chair for Arcus therapeutics. All other Topic Editors declare no competing interests with regards to the Research Topic subject.
Keywords:
Hepatocellular Carcinoma, antibody-based immunotherapy, Monoclonal antibodies, cancer vaccine, checkpoints inhibitors
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.